Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd ADR (NQ: ZLAB )

14.07 -0.15 (-1.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 465,946
Open 14.20
Bid (Size) 14.07 (2)
Ask (Size) 14.08 (8)
Prev. Close 14.22
Today's Range 13.93 - 14.23
52wk Range 13.48 - 38.88
Shares Outstanding 956,637,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
From Zai Lab Limited
Via Business Wire
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
From Zai Lab Limited
Via Business Wire

Performance

YTD
-46.01%
-46.01%
1 Month
-22.99%
-22.99%
3 Month
-40.28%
-40.28%
6 Month
-40.15%
-40.15%
1 Year
-62.52%
-62.52%

More News

Read More
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
From Zai Lab Limited
Via Business Wire
Recap: Zai Lab Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Via Benzinga
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Via Benzinga
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
From Zai Lab Limited
Via Business Wire
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
What Happened With Zai Lab Stock?
Via Benzinga
Shhh! 7 Small-Cap Stocks That Can Double by 2025
Via InvestorPlace
Stock Disconnect Triggers Investor Exodus From CStone Pharma
Via Benzinga
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in March Investor Conference
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Top 5 Health Care Stocks That Are Preparing To Pump In February
Via Benzinga
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024
From Zai Lab Limited
Via Business Wire
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
From Zai Lab Limited
Via Business Wire
Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Zai Lab Announces Participation in January Investor Conference
From Zai Lab Limited
Via Business Wire
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
From Paratek Pharmaceuticals, Inc.
Via GlobeNewswire
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.